The variable expressivity of FH can be attributed to modifier variants in LDLRAP1, EPHX2, ABCG5, ABCG8, LIPA, or APOE genes or polygenic risk variants (2, 43, 44). This evidence concerns the gene ABCG5 and familial hyperaldosteronism.